

OVERVIEW

Our Board of Directors has evaluated and updated the DIA **Mission, Goal, and Vision** to reflect the new challenges and opportunities facing DIA and the way DIA is changing to meet them. Throughout this process, the Board was often and profoundly reminded of the wisdom of DIA's founders, who established a set of principles that simultaneously and equally benefit DIA members, their employers, DIA as an organization, and the industry as a whole. DIA is guided by these principles to this day.

Mission

To serve and develop members by providing a neutral, global forum that promotes the exchange of information critical to their professional performance and achievement.

Goal

To be the most effective means for members to obtain the knowledge they need to advance their career, their profession, their organization, and their industry.

Vision

To be universally recognized as the world's premier member-driven organization encompassing the full continuum of disciplines in the pharmaceutical and related industries and to be valued as the professional development authority.

Principles

- DIA is an association of individual members
- DIA is multidisciplinary and open to everyone
- DIA is led by member volunteers
- DIA is committed to the continuously improved professional practice of members
- DIA provides a neutral forum for the dissemination of information
- DIA is international in scope and global in perspective
- DIA is a not-for-profit organization.

PRESIDENT'S MESSAGE

Irwin Martin, PhD, President of DIA, made the following remarks about the state of the Association on June 17, 2002, before the opening of the Plenary Session of DIA's 38th Annual Meeting.

“On behalf of the Board of Directors of the Drug Information Association, welcome to the 38th Annual Meeting of the DIA. Before we begin the plenary session, tradition, and our by-laws, dictates that we hold our annual business meeting.

Thank you all for your interest in and support of your association. Congratulations and thanks to all who worked so hard to make this meeting the success that I'm sure it will be.

In January of every year, the President of the US presents the “State of the Union” in a speech to the American public. If you will, please allow me a few moments to present the “State of the Association.”

The State of the Association is strong. We had another very successful year in 2001, and it looks like 2002 will be even more successful. Some highlights follow:

Revised Mission, Goals and Vision

Your board of directors and others spent a great deal of time aligning ourselves behind these concepts. They really do capture our ideals for this association and help direct all decision-making.

Worldwide Headquarters Building

Later this summer, the DIA office in Fort Washington, PA will be relocated to our new permanent location in Horsham, PA. DIA was able to construct this building due to wise investments made in the 1990s and excellent timing in the year 2000! We feel the building will return many member benefits, including a lower global operating overhead for your Association, as well as facilities to support many programs and training initiatives.

Membership Growth

We continue to grow at a rate of approximately 10% per year. In the past five years, we have doubled our number of members, with a membership of over 27,000 at the end of 2001.

Programming Sets Records

In 2001, DIA held 88 meetings, training courses, and satellite video conferences in North America; 27 meetings and training courses in Europe; six meetings in Japan; three meetings elsewhere in the world. Five meetings in North America were cancelled because of the September 11 tragedy.

DIA Foundation

The DIA Foundation is a not-for-profit association formed this year for the sole purpose of coordinating all of DIA's charitable activities. Research grants, fellowships, and grants for meetings outside our core regions will all be funded via the Foundation. This arrangement will help assure a stable, predictable charitable resource that will not impact other DIA operations.

Strong Fiscal Performance

When compared with similar nonprofit organizations in the US, DIA's performance is above average. We continue to be efficient and provide reasonably priced meetings to address the needs of a diverse membership.

DIA Europe Expands

This week, the DIA staff in Basel is unpacking boxes and moving into a larger office suite in Basel, Switzerland. The DIA Eurometing attracted more than 1400 attendees to this year's meeting in Basel. The meeting now has 12 concurrent tracks. We are expecting even a larger turnout in Rome in 2003.

DIA Japan Successes

DIA established an LLC office in Japan. The program committees there increased the number of meetings by 50% (up to six) and increased the membership by 45% (up to approximately 1000). Japan is now second only to the US in membership.

Expansion of SIACs

In both North America and Europe, we are greatly expanding the number, scope, and responsibilities of the Special Interest Area Communities. The Board is committed to obtaining input, ideas, and help from as many members as are interested. We encourage you to join an SIAC and help the Association better meet the needs of your organization.

eLearning

At the end of this summer, DIA will be rolling out the first of its eLearning initiatives. The Medical Communications Certificate program is a completely online, self-paced, modular program with ACPE continuing education credits.

Information Technology Improvements

The DIA office has installed a new association management system to better understand and meet your needs. The web page has been redesigned and improved, with your need for easy information access in mind.

Given all these successes, are we satisfied? Not yet. We continue to strive to meet your needs and grow your organization. But we need your input and your help. This is your Association. We depend on member volunteers for ideas and programming. We are always looking for future leaders of this Association.”

Irwin G. Martin, PhD

President

Drug Information Association

STRATEGIC PLAN

In 1997, DIA adopted a Strategic Plan to serve as the basis for its annual operating plans and budgets. This Strategic Plan sets forth how DIA will respond to changes in the medical, scientific, and regulatory (legal) environments, as well as political, social, and economic changes, and reflects DIA's priorities and experiences. DIA develops timing, budget, and resource implications of proposed initiatives, evaluates them against these strategic objectives, and monitors ongoing progress under this plan on a quarterly basis.


This Plan establishes the framework within which DIA can:

- Anticipate important emerging issues
- Focus on major initiatives
- Implement these initiatives over time
- Allocate its resources more efficiently

This Strategic Plan is centered on five core initiatives to reach these four strategic objectives:

- Developing a global organization
- Responding to changes in the external environment
- Responding to members' needs
- Expanding the scope of DIA membership

The following diagram illustrates how the Strategic Plan informs and directs daily operations in meeting members' needs.



A description of each core initiative and summary of actions taken to meet the goals of each initiative follows.

Core Initiative: Board Procedures:

Determine the overall DIA strategic and policy objectives, review and monitor plans and progress for meeting these objectives, and determine the most optimal administrative structure for supporting DIA needs on a global basis.

Actions Taken:

DIA continues to conduct strategic and policy planning activities and has worked toward revising the association By-laws to more accurately reflect the current and planned responsibilities of the association and to make it easier for the Board and association staff to take better actions on members' behalf.

Core Initiative: Membership Expansion:

Expand the base of DIA membership beyond its current constituents in order to advance the goals of DIA and to secure wider and more diverse inputs on future programming.

Actions Taken:

DIA Member Profile

DIA has taken major steps in expanding services to members. Of all these steps, the most important may be a simple little form that collects some general information about members – the member profile.

Implementation of the profile is linked to a new member management software program developed specifically for associations and organizations like DIA. It will dramatically upgrade the ability to customize communications and assist members in accessing information and receiving program notices related to specific areas of interest. It will also improve online registration, renewals, and other transactions.

This form includes questions on level of industry experience, educational background, length of time in current position, current work setting, primary focus of full-time work, and similar questions. It will be added to registrations, membership applications, and the web site.

New DIA Membership Kit

DIA Member Services has also developed and produced a new membership kit, which was sent to all new and renewing DIA members in May 2002. It was designed to be a one-stop source for information about the Association, its benefits, and other pertinent information. The membership kit includes:

- A membership booklet that explains all aspects of DIA including its mission, history, goals, governance, and benefits of membership
- A membership application
- A brochure on Special Interest Area Communities (SIACs), their role in DIA, the structure of a typical SIAC, and the benefits of participating

Easy-to-use contact postcards to let DIA know of your interest in participating in a SIAC, to volunteer to serve as a speaker or author or on a committee, or to refer a new member
A personalized DIA membership certificate.

New Membership Management Software System

DIA has also made substantial changes to its membership and business management IT systems, most notably a new, externally hosted association management system that allows all DIA offices to access data and applications. The member portal on the DIA web site also provides for sophisticated member self-service, eLearning, and tracking members' preferences, interests, and activities, plus more comprehensive meeting management and financial functions. This will allow DIA to assess members' needs and allocate resources accordingly. While most of these changes went largely unnoticed by members, it is members who will benefit most directly from these changes.

“More Content to More Members”

DIA always strives to improve both the quality and quantity of the content and other communications it delivers to members. Enhancements that DIA members will notice in 2002 and beyond include:

Meetings Plus

- Some meetings will be conducted in multiple regions
- Some meetings will be held in venues able to host high quality, interactive events
- Many DIA meetings will be audio or videotaped for sale to members not in attendance
- Some meetings will be broadcast via videoconference, audioconference, or diahome.org
- If open to the general public, DIA can bring meetings to members' companies.

Expanded Publication Program

- Additional or special issues of the *Drug Information Journal* will be produced
- The *DIA Forum* has been relaunched as a practical source of information
- Special publications will be created to distribute information on key topics.

Increased Member Interaction

- DIA will conduct a needs assessment to determine and guide program development
- Online networking opportunities will be enhanced to maximize member interaction.

Expanded Member Resources

- DIA will provide access to externally-produced books and educational materials
- DIA will forge relationships with allied societies, expanding access to additional networks and information.

Core Initiative: Partnerships:

Build partnerships with related organizations to create synergistic opportunities for both programming and training: Explore partnership opportunities with academic, regulatory, or other professional not-for-profit organizations as a means of expanding program offerings to DIA

members, and establish partnerships with other organizations providing training courses or faculty.

Actions Taken:

During the period covered by this Annual Report, DIA collaborative programs and events included:

*An Introduction to the Center for Drug Evaluation and Research (CDER)
Georgetown University, USA*

DIA worked with the Food & Drug Administration (FDA), Regulatory Affairs Professionals Society (RAPS), and the Center for Drug Development Science (CDDS) at Georgetown on the development of a pilot workshop, “An Introduction to the Center for Drug Evaluation and Research,” or “CDER 101.”

*Australian Pharmaceutical Physicians Association (APPA) Symposium
Sydney, Australia*

DIA was a major sponsor of the APPA symposium on therapeutic safety monitoring involving prescription pharmaceuticals, devices, self-medication, biotech products, and other therapeutic goods, organized in conjunction with the Department of Clinical Pharmacology and Toxicology, St. Vincent’s Hospital, Sydney, and including expert international opinion from European, Singaporean, American, and local speakers.

*CADREAC Delegates Open Forum
Riga, Latvia*

DIA hosted this meeting to disseminate news from the Collaboration Agreement between Drug Regulatory Authorities in European Union Associated Countries (CADREAC) immediately following that group’s annual meeting. CADREAC signatories are state regulatory authorities for human medicinal products in Bulgaria, the Czech Republic, Cyprus, Estonia, Hungary, Latvia, Lithuania, Poland, Romania, Slovak Republic, Slovenia, and Turkey.

*Châtenay-Malabry, Paris XI Celebration Day
Paris, France*

Hundreds of pharmacy students and invited industry guests heard world leaders address the challenges and issues involved in developing and regulating drugs at a special program held at the University Paris XI, outside of Paris. DIA board members contributed to these presentations.

*Conference of the Pan-European Regulatory Forum on Pharmaceuticals (PERF)
Tallin, Estonia*

DIA provided logistical support for the efforts of the European Agency for the Evaluation of Medicinal Products and the European Commission at the second PERF Conference.

*DIA – Australian Therapeutic Goods Administration (TGA) Fellowship Program
“Post-Market Vigilance of Therapeutic Goods”
Canberra, Australia*

DIA provided \$75,000 to fund the 2001 DIA – TGA Fellowship Program, held at the Australian Therapeutic Goods Administration (TGA) at Canberra in the Australian Capital Territory. The

2001 DIA-TGA Fellows came from China, Indonesia, Malaysia, Singapore, Thailand, and Vietnam.

*Fifth European Regulatory Affairs and Scientific Conference
Paris, France*

Phillipe Brunet, head of the pharmaceuticals unit at the Enterprise Directorate of the European Commission (EC), and EC Principal Administrator Arielle North, represented the EC at the Fifth Regulatory and Scientific Conference DIA EuroMeeting in Paris.

*First Annual Pharmaceutical Product Development Scholarship Conference
“Industries in Transition: Pharmaceuticals and Biotech in the New Millennium”
West Chester University, USA*

DIA co-sponsored West Chester University's first annual Pharmaceutical Product Development Scholarship Conference to raise scholarship monies for a new program in pharmaceutical development.

*First Latin American Congress of Clinical Research
Mexico City, Mexico*

DIA hosted the first Latin American Congress of Clinical Research. DIA President Irwin Martin and DIA Steering Committee of the Americas member and Executive Director of AFAMELA, Mexico's over-the-counter industry association, Héctor A. Bolaños, spoke about DIA and what it offers to those who work in the discovery, development, regulation, and use of medicines and healthcare technologies.

*International Conference on Pharmaceutical Affairs
Co-sponsored by the US Pharmacopeia Drug Quality & Information Program (with the United States Agency for International Development Office of Population, Health and Nutrition) and DIA
Kathmandu, Nepal*

This conference was designed to give individuals from pharmaceutical excipient manufacturers, quality assurance / quality control, procurement, pharmaceutical research and development, consumer health advocates, and government regulators, an understanding of the global regulatory environment and its impact on developing countries, and was jointly organized by the Department of Drug Administration, Ministry of Health, Nepal, DIA, USPDQI, and the Graduate Pharmacists Association of Nepal (GPAN).

*Pharmaceutical Specialist Education Models in Europe
Pharmcenter, University of Basel, Switzerland*

A special satellite of DIA EuroMeeting Basel 2002, sponsored by the European Council of Pharmaceutical Medicine (ECPM), the European Federation for Pharmaceutical Sciences (EUFEPS), the International Federation of Associations of Pharmaceutical Physicians (IFAPP), and DIA, was held to discuss the need for and composition of pharmaceutical specialist education programs.

*Postgraduate Course in Clinical Pharmacology, Drug Development, and Regulation
Jointly sponsored by Tufts University School of Medicine, Tufts Center for the Study of Drug
Development, and DIA*

Boston, Massachusetts USA

Given annually for nearly thirty years, this course is designed for physicians, pharmacists, nurses, PhDs, and others who are new to the regulatory affairs divisions of government agencies, the pharmaceutical industry, or other professional groups involved in drug development and clinical pharmacology. It provides a broad and basic overview of topics related to pharmaceutical development and regulation, divided into Clinical Trials, Experimental Design, Drug Development, and Clinical Pharmacology areas.

*Spring Congress of American Medical Informatics Association
Scottsdale, AZ USA*

DIA cooperated with the following organizations with a shared interest in the objectives of the American Medical Informatics Association at their 2002 Spring Congress: United States Department of Veterans Affairs, United States Food and Drug Administration, Institute for Safe Medical Practices, American Society of Health-System Pharmacists, Massachusetts Medical Society, Mayo Foundation for Medical Education and Research, Clinical Data Interchange Standards Consortium, Scottsdale Institute, American Pharmaceutical Association, and FDA CDER.

*University of Maryland Post-Doctoral Fellowship
University of Maryland, USA*

DIA provided \$59,992 to support the University of Maryland Postdoctoral Fellowship in Outcomes Research.

Core Initiative: Steering Committee Procedures:

Review Steering Committee procedures, define the intent of the Steering Committees, define the relationship between the Steering Committees, Board, and local offices, define the Steering Committee for International Development (IDC) charter, and establish operating procedures that are appropriate and specific for each regional steering committee.

Actions Taken:

Special Interest Area Communities (SIACs)

DIA Special Interest Area Communities (SIACs) determine the professional development needs within specific professional interest areas and their affiliated DIA members. SIACs serve as forums for DIA members who wish to build affiliation with DIA while taking part in and building a global structure for networking and leadership development as well as defining and prioritizing the content of various DIA educational offerings.

Recognizing that the simplest first step to creating products and programs that meet members' needs is to create a structure that allows members to express those needs, the Steering Committee for North America (SCNA) has been reconstituted so that SIAC representatives comprise the majority of this Committee. Representation on the SCNA from each and every SIAC will enable

the Committee to design products and services that more comprehensively meet the needs of the membership. This change, approved in a vote taken at its March 2002 meeting, creates a direct link between the grassroots volunteer SIAC communities to the leadership of this Steering Committee. The SCNA unveiled this “new look” at its June 2002 meeting held in conjunction with the 38th Annual Meeting in Chicago.

SIAC initiatives are quickly evolving; the number of SIACs, for example, has grown from 14 in December 2001 to 22 in June 2002. DIA is working very hard to help advance awareness of SIACs and to increase membership in each of these communities.

Core Initiative: Training Topics & Expansion:

Expand and update training courses to reflect the changing health care environment, develop a procedure to solicit training needs globally and to establish courses which address global and regional requirements, and evaluate the need for developing a training center.

Actions Taken:

Mergers and acquisitions and evolving science and technology make it increasingly important to keep abreast of current issues and trends. DIA gives members the advantage of an expansive network of career and professional development opportunities.

Center For Career & Professional Development (CC&PD)

The new Center for Career & Professional Development (CC&PD) will centralize and broaden DIA’s focus on helping its members strengthen their personal and professional performance by sharing information to continually upgrade their knowledge and skills. To accommodate its internationally dispersed membership, the CC&PD will feature distance and on-demand educational programs that members can access through the DIA web site. Core and special interest area curricula specific to the pharmaceutical and related healthcare industries will be supplemented by more broad personal development courses to improve presentation skills, interview skills, oral and written communication skills, and more.

Training Courses

The DIA training program currently consists of nearly twenty topics grouped along the major functional areas of pharmaceutical development and regulation and are developed for entry, intermediate, and advanced levels. Courses are offered several times per year and are offered year-round throughout the US and Europe.

DIA training programs are more important than ever because many companies have stopped providing industry-related training and only provide product-specific or operating training internally. Mergers and acquisitions, new startup companies, career changes, and professionals who need broader knowledge of “the big picture” all contribute to the need for DIA training courses.

DIA is implementing a range of distance or on-demand educational programs. Training course workbooks, reference materials, audiotapes, videotapes, and slide presentations will soon be

available for access via the DIA website. Core and interest area curriculum, certification, and Continuing Medical Education (CME) credits are part of DIA's training and professional development plan.

Not only has the traditional training program grown in size, but DIA is also expanding its scope to address the broader career and professional development needs of its members through personal skills enhancement courses such as presentation skills, interviewing skills, and oral and written communication skills.

The Board of Directors has also unanimously approved a proposal to conduct training courses at members' facilities. In the past, DIA did not offer this service because all DIA meetings must be open to the community at large. After September 11 2001, however, DIA re-evaluated all of its programs and policies and adopted a slate of programs designed to fulfill DIA's mission by supplementing traditional live, open meetings with alternatives that preserve those values.

DIA WEB SITE

As the internet becomes increasingly central to communications and transactions, more DIA members visit the DIA web site more often than ever before. While DIA has regularly enhanced web site content and functions, DIA's expanded information dissemination program required upgrading the DIA web site. Underlying everything is a new architecture and language established to accommodate the new association management system software.

Several of the most frequently visited areas of the DIA web site have been moved to the "Members Only" section of the web site. Members need their DIA PIN to access these functions:

- Searchable online CSO Directory

- Searchable online DIA Member Directory

- Searchable job bank of hundreds of positions that can be searched by company, by discipline, or by region, and accepts postings of new available positions

- Selected presentations from key DIA meetings

- Blended learning and self-paced online eLearning course materials

DIA also created and filled the position of IT Director to support the Association's rapidly expanding information technology functions.

EXTERNAL ENVIRONMENTS & MEMBER NEEDS

Covering A Broad Spectrum Of Drug Development Issues

The DIA mission charges us to provide a neutral global forum for the exchange and dissemination of information. That forum, in which ideas, information, methodology and opinions are provided, is shared among and between many DIA constituents.

DIA sponsors meetings, workshops and training courses, highly responsive to the rapidly evolving, multi-disciplinary needs of its international membership. The content and format of these activities are determined by a proactive, participatory membership. These activities address a broad range of pharmaceutical, regulatory, and drug development topics.

In 2001, DIA held 124 meetings, training courses, and satellite videoconferences: 88 in North America, 27 in Europe, six in Japan, and three in other places. Five additional events scheduled for the fourth quarter of 2001 in North America were cancelled after the events of September 11.

DIA continues to expand meeting topics in response to continually changing new drug development, data management, and business technology.

DIA meetings covered trends and provided forums for discussion of the many topics of pharmaceutical discovery, development, evaluation, and regulation.

The broad spectrum of 2001 – 2002 DIA meeting subjects includes:

The Impact of the Internet on the FDA

The Electronic Pharmaceutical Enterprise: eProcesses from Discovery through Delivery

Current Issues in Personal Data Protection

Computer Validation From a Systems Perspective

Clinical Data Management and Document Management

Medical / Technical Writing and Communications

Project and Financial Management

Global Development Strategies for Emerging Diseases

Statistical Methodology in Clinical Research & Development

Surviving an FDA Inspection

Blending eLearning Solutions for the Biopharmaceutical Industry

Better Medicines for Children

September 11, 2001

The almost incomprehensible events of September 11 2001 changed the environment in which DIA supports its members and their activities. Recognizing that this horrific day may engender confusion and doubt about the future, DIA Executive Director J. Robert Assenzo and DIA President Irwin G. Martin composed a letter to all members of the DIA community. This letter was included in the *Drug Information Journal* published in October 2001 and reads in part:

“What is easy to comprehend is that our work must continue. We must all continue to strive to discover, develop, and evaluate the most effective pharmaceuticals, medical devices, biologics, and innovative new products that benefit people around the world. It is DIA’s mission to make sure that we provide you with the education and information necessary to do just that.

“DIA is committed to making sure that our work will move ahead. This will happen in several ways:

DIA is taking steps to replicate and reproduce our outstanding line-up of live meetings and bring critical content to as many members as possible.

Meetings that draw large numbers from geographically diverse pools will be conducted in multiple regions.

Meetings that can be broadcast via satellite will be placed in venues able to host high-quality, interactive events.

The majority of DIA meetings will be audiotaped or videotaped so members can obtain information when not able to participate in person.

Some meetings will be broadcast via diahome.org.

If open to the general public, DIA can even bring meetings to members’ companies.

In addition to these enhancements to DIA’s meetings, other information channels will also be improved.

Additional or special issues of the Drug Information Journal will be produced.

The DIA Forum will be relaunched as a practical source of information you need to do your job.

Special publications will be created to distribute information on key topics.

DIA will increase its communications both to and from members to ensure that we are meeting their educational and informational needs.

Needs assessments will be conducted across disciplines to determine what information is needed and in what format it is desired.

Online networking opportunities will be enhanced so that interaction between members is maximized.

Membership renewal and the benefits of membership will be emphasized and expanded, making DIA even stronger than before.

New products and programs will be developed that are designed to make the DIA community stronger.

Relationships with allied societies will be forged, expanding members' access to network and informational resources."

eLEARNING

To further address its members' career development needs, DIA launched its first eLearning initiative: A Medical Communications certificate program that provides comprehensive training in the field of medical communications practice for the pharmaceutical industry. This Medical Communications certificate was developed as a by-product of DIA's highly successful "Medical Communications Core Curriculum" taught for the past several years at the Annual Meeting. The perennial popularity of this session, the need to further education its members, and advances in internet and interactive learning technologies, were all factors in DIA's inaugural eLearning initiative, which incorporates CD-ROM, audio-, video-, and web-conferencing, and online courses and tutorials. The online certificate program is available for purchase through the DIA web site as an exclusive members' only feature. The courseware is browser-based and available for access through the DIA's Learning Management System (LMS) over the internet. Asynchronous modules enable learners to start and finish at their own pace and to pick up directly where they previously left off; internet accessibility enables learners to access their course materials at any time and from any location with internet access.

DIA PUBLICATIONS

Along with automatic eligibility to participate in its career development workshops and events, DIA members receive all DIA publications free of charge. In 2001 – 2002, DIA re-engineered and reintroduced two of these publications, the *DIA Today* and the *DIA Forum*. Combined with the *Drug Information Journal*, DIA now delivers one quarterly publication to members each month, each meeting a specific information need and content type. These publications are an important component in ensuring that DIA communicates as much useful information as possible to as many members as possible.

DIA also hired a Managing Editor to direct and support its publications to further ensure that they deliver high quality and timely content to members.

“DIA Today”

DIA Today was relaunched in 2001 and is circulated to members quarterly to communicate information about DIA programs and activities to DIA members. It features important news from major DIA conferences and workshops, and reports on the actions of the Board of Directors and of the regional Steering Committees and other committees that directly impact DIA members. It also includes notices of upcoming activities that benefit members and other information relevant to their professional experiences.

DIA Today contents generally include:

DIA Direction: The work of the Board of Directors and steering and other committees

DIA Program News: News of current and upcoming DIA programs, events, and publications

DIA Program Notes: News and perspectives from recent DIA programs, events, and publications

DIA Membership News: Information of membership programs and services

DIA Member Recognition: Highlighting accomplishments of DIA members.

“DIA Forum”

The *DIA Forum* was relaunched in 2002 as a complement to the DIA Center for Career & Professional Development by presenting practical, experience-based information from DIA’s numerous conferences, training sessions, and workshops, in an easy to read style. Circulated to members quarterly, it provides a vehicle for membership to share from their own experiences how changes in science, best practices, and policies and regulations, can impact their profession and career.

DIA Forum contents generally include:

Tips of the Trade: Short, practical articles featuring approaches and applications designed to enhance or improve performance of specific jobs or tasks

Networking: Examples of how to maximize the worldwide DIA member network

Open Forum: Commentary and opinion from the editorial board or membership

Training Topic: Sharply focused look at a session from one of DIA’s training courses or tutorials, complete with a post-test and continuing education credit

Electronic Learning Forum: Examples of the latest DIA audio-, video-, CD-, or web-based educational offerings plus tips for making the most of them

Interviews & Profiles: Showcasing a DIA member who has worked in interesting times or positively impacted their industry

Technical Topics of General Interest: Easy to understand summations of complex technologies or regulations that impact industry professionals

Future Forecast: Brief presentations of future trends or innovations that will impact the industry

Global Forum: News and articles related to career and professional development from around the world

Marketplace: A combination of DIA job bank and classified advertising, consultant bulletin board, and new product announcements

Special Skills: News and articles related to problem solving, coaching, presenting, writing, and other topics fundamental to professional performance.

“Drug Information Journal”

The *Drug Information Journal* is the official publication of DIA. This international and multidisciplinary peer-reviewed scholarly publication is circulated quarterly to members to:

Disseminate information on the discovery, research, development, regulation, utilization, and marketing of drugs, devices, biologics, and related products

Foster communication between educational, research, industrial, and governmental personnel engaged in the above activities

Provide a forum for the development of improved methods related to the above activities.

The full text of the current issue of the *Journal*, and abstracts of articles in seven different languages, are also available in the members’ section of the DIA web site.

Retiring DIJ Editor in Chief Thomas W. Teal

At the end of 2001, Mr. Thomas W. Teal retired as *DIJ* editor in chief after serving the association for eighteen years in this position. The final *DIJ* issue published under his leadership was introduced by a tribute letter from David M. Cocchetto and Roger W. Crosswell, both Past Presidents of DIA and members of the *DIJ* editorial board. Their tribute read in part:

“It is our great privilege and honor, as members of the Editorial Board of the Drug Information Journal, to write this letter to our fellow members of the Drug Information Association in order to pay tribute to Mr. Thomas W. Teal.

At the end of 2001, Mr. Teal is retiring from his position as editor in chief of the Drug Information Journal. Mr. Teal has served the association in this position for 18 years. Since this issue of the journal is the last one to be published under Mr. Teal’s leadership, we dedicate this issue to him in special recognition of his many contributions to our association.

Mr. Teal is one of the parents of the Drug Information Association (DIA), and he has played an essential role in the organization’s origin, growth through adolescence, and expansion. As many of you know, Mr. Teal served as executive director of DIA from 1979 to 1991. In addition, he has served at the helm of the Drug Information Journal as its editor in chief from 1983 through 2001. Tom has blessed the association with his leadership, mentorship, honesty, salesmanship, professionalism, and dedication.

Mr. Teal has contributed an immeasurable amount of time, energy, and expertise to this journal. Further, he has been a valued friend, mentor, and professional colleague to all of us who have supported the journal by service on the Editorial Board. Our views have been welcome, and actively solicited, in building the journal and recruiting contributing authors. Some of us have had the irreplaceable experience of serving (with Tom’s coaching and support) as a guest editor of a special issue of the journal – just one example of his creative recruitment of individuals and teams of authors to take the journal into new areas and generate informative volumes for the members of the DIA.”

New DIJ Editor in Chief Kenneth I. Kaitin, PhD

Kenneth I. Kaitin, PhD, a Past President of DIA and member of the *DIJ* editorial board since 1991, was named editor in chief of the journal effective January 1, 2002.

Dr. Kaitin is the Director of the Tufts Center for the Study of Drug Development at Tufts University, where he studies national and worldwide trends in pharmaceutical innovation, regulation, and public policy. He is also Assistant Professor of Pharmacology and Experimental Therapeutics at Tufts University School of Medicine.

Dr. Kaitin is a member of the New England Institute for Healthcare Research and Innovation, and he serves on the faculty of the European Center for Pharmaceutical Medicine. He is also a member of the American Society for Clinical Pharmacology and Therapeutics, the New York Pharma Forum, and Regulatory Affairs Professionals. Dr. Kaitin plans to establish discipline-specific section editors who will identify important authors and topics for the journal, and to add a European associate editor in chief to the masthead.

CSO Directory

Distributed annually at no charge to members, the DIA *Contract Service Organization (CSO) Directory* serves as a reference guide which details services and products provided by several hundred international organizations in support of the discovery, development, and utilization of pharmaceuticals, devices, and biotech or genetic products, cross-referenced into various indices to improve its utility. The online version, available in the members' section of the DIA website, allows members to contact these service organizations directly via web links or e-mail. The expanded IT program at DIA headquarters makes it simple for DIA staff to help these organizations maintain their listings; plans for future enhancements include providing secure log-ins to these organizations so they can update their own listings in real time.

DIA Membership Directory

DIA also provides a searchable DIA Membership Directory in the members' section of the DIA web site. Members control their own information in this database under the strictest privacy and security guidelines.

PHILANTHROPY and GOODWILL

Supporting Professional Growth and Development

DIA supports growth and development of pharmaceutical professionals by sponsoring awards and research grants. In 2001, these grants and awards included:

Fellowships: \$134,992

Research Grants: \$108,504

Poster Awards: \$6,400

Discretionary Awards: \$52,750

Distinguished Career Award: \$1,000

Francke Award: \$1,000

The DIA Research Grant Program funds grants (in amounts not to exceed \$25,000 each) to encourage and foster research in pharmaceutical and biotechnology product development, regulation, marketing, utilization, and surveillance, among others. The Research Grant proposals chosen to receive funding in 2002 were:

Clement Gwede, PhD, University of South Florida, USA

Factors Associated with Workload and Burnout in Clinical Research Coordinators

Carol Hope, PharmD, Regenstrief Institute for Health Care, USA

Evaluation of a Medication Knowledge and Skills Assessment Tool

Kathleen Mazor, EdD, University of Massachusetts Medical School / Meyers Primary Care Institute, USA

How Pharmaceutical Companies Communicate with Healthcare Providers: A Systematic Evaluation of Dear Doctor Letters

Ralph Meer, University of Arizona, USA

Labeling of Dietary Supplements: Industry Compliance and Consumer Awareness

Sheila Shulman, LLB, MPH, State University of New York at Buffalo, USA

Direct-to-Consumer Advertising and the Learned Intermediary Defense: A Qualitative Analysis of Court Decisions

Zhang Sumin, National Center for ADR Monitoring, China

The Influence of Education on Pharmacovigilance of Health Professionals

Albert Wertheimer, Temple University, USA

Quantitative Overviews of Studies of Adherence with Prescribed Drugs

Almut Winterstein, PhD, University of Florida, College of Pharmacy, USA

Nature and Etiology of Medication Errors of Omission – Creating an Advanced Knowledge Base through Solicited Error Reporting and Systematic Analysis

DIA Foundation

DIA formed a new not-for-profit corporation in the Commonwealth of Pennsylvania, the DIA Foundation, to support charitable DIA activities around the world. The mission of the DIA Foundation is to globally provide research grants to fund deserving proposals and to provide grants to national health authorities or accredited educational institutions to provide training fellowships in healthcare product development, life-cycle management, or regulatory review. The DIA Foundation Board of Directors consists of the last three DIA Past Presidents, past Chairs of the Steering Committees for North America and for Europe, and members at large. This Board will meet regularly throughout the year. By-laws for the DIA Foundation were unanimously accepted by the DIA Board of Directors in September 2001; the DIA Foundation became fully functional in February 2002.

COMMITTEES

Foundation Committee

The DIA Foundation was formed as a public charity to support DIA. Its mission is to globally provide research grants to fund deserving proposals and provide grants to national health authorities or accredited educational institutions to provide training fellowships in health care product development, life-cycle management or regulatory review. By-laws for the DIA Foundation were unanimously accepted by the DIA Board of Directors in September 2001; the DIA Foundation became fully functional in February 2002.

International Development Committee

The International Development Committee (IDC) continues to work to expand DIA's presence and activities throughout the world. IDC activities are tailored to the different local conditions in regions where significant drug development activities are occurring and in areas of emerging growth. IDC advances the DIA work of providing a forum for the development of improved methods of presenting, communicating, and using research data generated from chemical, toxicological, pharmacological, and clinical studies by influencing growth in all regions.

Information Technology (IT) Committee

This past year was pivotal for DIA in Information Technology (IT). First, DIA created an overall IT strategy which encompassed the underlying IT architecture and the way we communicate with members. The entire DIA Internet presence, particularly the DIA Web site, was redesigned to reflect this overall strategy by facilitating ease of use, enhanced member communication, seamless integration with the new Association Management System (AMS), and clear, crisp navigation. The new externally-hosted AMS allows every DIA office to access and share systems, software and other tools, and data and information. The DIA Web site was reconstituted as a member portal which provides for sophisticated member self-service, integration of eLearning, member preference and interest tracking, plus comprehensive meeting management and financial functions. The DIA management team was expanded to engage a Director of IT to lead DIA's effort to meet the association's rapidly expanding information technology requirements.

Japan

As DIA activity in Japan has expanded, the number of DIA members from Japan has correspondingly increased. DIA presented six programs in Japan, including the annual Biostatistics, Clinical Data Management, Medical Writing, and Medicinal Information Processing programs, as well as the first annual Workshop for Global Pharmacovigilance, entitled "International Comparison of Pharmacovigilance."

Steering Committee for Europe

The Steering Committee for Europe (SCE) is responsible for proposing conference and workshop programs that contribute to the development of the DIA in the countries of the European Union (EU), the countries participating in the enlargement process of the EU, the countries of the European Economic Area (EEA), the European Free Trade Association (EFTA),

the Middle East, and the countries assigned by the DIA Board of Directors. The SCE contributed to the success of the 2001 and 2002 EuroMeetings, respectively held in Barcelona, Spain and Basel, Switzerland. In terms of size and content, the EuroMeeting has become the second most important DIA event, second to the only the Annual Meeting.

DIA conducted approximately thirty programs, seminars, training courses, and other meetings in Austria, Belgium, Denmark, Estonia, Italy, France, Germany, Latvia, the Netherlands, Portugal, Scotland, Spain, and the United Kingdom, during this time period. These included the annual programs on Medical/Technical Writing, Clinical Data Management, Electronic Document Management (EDM), European Scientific and Regulatory Affairs, and an International Workshop on Statistical Methodology in Clinical R&D.

In addition, DIA raised its profile in countries where low membership numbers might be improved, such as Turkey, by conducting programs there, some for the first time.

Steering Committee for North America

The Steering Committee for North America (SCNA) is responsible for ensuring the development, implementation, and evaluation of high quality initiatives that are held in North America. SCNA members provide leadership and guidance to the North American component of the Special Interest Area Communities (SIACs) toward the objective of continued educational development for DIA's membership. The SCNA contributed to the success of the 2001 and 2002 Annual Meetings, respectively held in Denver and Chicago. The Annual Meeting remains DIA's most important gathering. DIA conducted nearly eighty training courses, programs, and other meetings in the United States, Canada, and Mexico. These featured the first Latin-American Congress of Clinical Research and first Field-Based Medical Programs Directors' Workshop and also included the annual Document Management Conference, the Computer Validation Conference, the Medical Communications Workshop, the Symposium on Quality of Life Evaluation, the Biotechnology Conference, the Pharmaceutical & Healthcare Information Management Workshop, and the DIA/FDA Project Management Workshop.

A formal Standard Operating Procedure (SOP) was developed and approved for the SCNA. The SCNA was reconstituted so that SIAC representatives comprise the majority of this committee. This increased SIAC representation and participation will enable the SCNA to design products and services that more comprehensively meet members' needs. This change creates a direct link between the grassroots volunteer SIACs and the SCNA leadership. The SCNA unveiled this new look at its June 2002 meeting.

A representative from the continuing education committee was appointed as a liaison to the SCNA, in order to comply with certain continuing medical education requirements.

Special Interest Area Communities (SIACs)

SIACs are the fundamental unit for DIA because it has representation from all organizational levels within a particular discipline. Every Steering Committee is built from and upon these Communities. A SIAC needs assessment / content development plan was distributed as a guideline to help SIACs identify and deliver content that meets members' needs.

Training Committee

DIA training courses remain very popular; attendance is up in most courses and DIA training course faculty continues to receive excellent ratings. Courses from the US continue to be offered in Europe. In 2001, DIA was reaccredited by the Accreditation Council for Continuing Medical Education (ACCME) as a provider of continuing medical education. Applications for accreditation from the American Council on Pharmaceutical Education (ACPE) and the International Association for Continuing Education & Training (IACET) were also submitted. DIA engaged in partnerships with several universities: The Massachusetts College of Pharmacy continues to serve as host for DIA's combined Regulatory Affairs course, and DIA presented its combined Regulatory Affairs I & II curricula at West Chester (PA) University then provided a portion of its residual proceeds from this course toward the University's Pharmaceutical Product Development degree program. Most notably, the first formal collaboration between a DIA training program and a university degree program was consummated with the University of Southern California (USC), whose Masters Program in Regulatory Science incorporates DIA's combined Regulatory Affairs I and II curricula. In Europe, DIA continues to participate in a Working Task Force, jointly sponsored by the European Center of Pharmaceutical Medicine (ECPM), the European Federation for Pharmaceutical Sciences (EUFEPS), and the International Federation of Associations of Pharmaceutical Physicians (IFAPP), that is engaged in collaborative discussions with several major universities.

AWARDS

Recognizing Excellence and Service to DIA

DIA members who have sustained a level of outstanding service to DIA over an extended period of time are given special recognition for their service with the *Special Recognition Award*. In 2002, the DIA recognized **Brenton E. James, BSc, FBIRA**, for his outstanding service.

The *Distinguished Career Award* recognizes an individual who has established a record for excellence in drug information science research, and has contributed to the expansion and improvements of drug information generation, processing, or use. The recipients of this Award for 2002 were:

Professor Jean-Michel Alexandre, MD, European Georges Pompidou Hospital, Paris
L. Bruce Rowsell, Canada

Each year, DIA presents *Outstanding Service Awards* to individuals who have provided outstanding service to DIA. The recipients of this Award for 2002 were:

Dr. Eric Abadie, MD, Syndicat National de l'Industrie Pharmaceutique, France
Dr. Philippe Bouissou, PhD, Pfizer Central Research, UK
Dr. Teresa P. Dowling, PharmD, AstraZeneca, USA
Professor Charlotte DuPont, DESS de Développement et Enregistrement International des Médicaments, France
Dr. Bern Eberwein, PhD, German Medicines Manufactures Association, Germany
Dr. Gerald A. Faich, MD, MPH, Pharmaceutical Safety Assessments, Inc., USA
Linda S. Hostelley, Merck Research Laboratories, USA
Dr. Kenneth I. Kaitin, PhD, Tufts Center for Study of Drug Development, USA
Dr. Cynthia Kirk, RAC, PhD, Quintiles, USA
Professor Edmund Jon Deoon Lee, PhD, National University of Singapore, Singapore
Dr. Randy Levin, MD, FDA CDER, USA
Dr. Andrew P. Marr, PhD, GlaxoSmithKline R&D, UK
Dr. C. Daniel Mullins, PhD, University of Maryland, USA
Dr. Yasuo Ohashi, PhD, University of Tokyo, Japan
Dana D. Rife, MBA, Johnson & Johnson Finance Corporation, USA
Dr. Jean-Louis Robert, PhD, National Health Institute, Luxembourg
Professor Joachim Röhmel, PhD, Federal Institute for Drugs & Medical Devices, Germany
Dr. Akira Sakuma, PhD, Organization for Pharmaceutical Safety & Research, Japan
Dr. Per Spindler, PhD, Danish Medicines Agency, Denmark
Atsushi Tsujii, Amgen Ltd., Japan
Dr. Michael J. Umen, PhD, Michael Umen & Company, Inc., USA
Dr. Stephen E. Wilson, DrPh, FDA CDER, USA

Dr. Ellick Wong, PhD, Pharmacia Corporation, Singapore

The *Donald E. Francke Award* was established to honor Dr. Francke, President of DIA 1969-1970, who chaired the DIA Publications committee from 1965-1971 and edited the *Drug Information Bulletin* (the forerunner of the *Drug Information Journal*). The award is given to the author(s) of an article that makes a significant contribution to the drug information literature and was published in the Journal during the year. The recipient of this Award for 2002 was:

Christy Chuang-Stein, PhD

For her article *Recent Advancements in the Analysis and Presentation of Safety Data* (Issue 2, Volume 35)

FINANCIAL INFORMATION

Investing in Our Future

DIA is a financially independent, not-for-profit organization. Its primary sources of revenue are membership dues and symposia, workshops, meetings, and conferences. DIA does not accept contributions of any kind from any source.

DIA sponsors funding in support of fellowships and research grants and awards.

The Unrestricted Net Asset balance was approximately \$11.1 million as of December 31, 2001.

DIA funds are conservatively invested in a combination of money market and mutual funds. Legg Mason and United Bank of Switzerland manage these funds for the Association. Legg Mason, an investment company, manages short-term and long-term reserve accounts, which consist of money market, bond, and mutual funds. United Bank of Switzerland manages investment funds that are Euro and Swiss Franc money-market instruments.

Investment strategies are regularly reviewed during the year at meetings of the DIA Board of Directors and of the Financial Planning Committee. Dr. Stuart Cummings, MS, PhD, Merck, Sharp & Dohme (Europe), Belgium, serves as Secretary / Treasurer for the Association, and serves as Chair for the Financial Planning Committee.

DIA made settlement on the purchase of the parcel of land upon which the new worldwide headquarters building will be located. Construction began in October 2001 and was completed in July 2002. Even though most DIA members will never visit the new headquarters building, there is a direct benefit to members of the association owning its offices as a long-term investment in an asset that will grow in value from year to year.